Show simple item record

dc.contributor.authorDe Ruysscher, D
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorLe Pechoux, C
dc.contributor.authorPeeters, S
dc.contributor.authorBelderbos, J
dc.date.accessioned2015-01-22T15:29:45Z
dc.date.available2015-01-22T15:29:45Z
dc.date.issued2014-12
dc.identifier.citationHigh-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. 2014, 15 (13):e620-e624 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid25456380
dc.identifier.doi10.1016/S1470-2045(14)70345-6
dc.identifier.urihttp://hdl.handle.net/10541/338674
dc.description.abstractAs the prognosis of lung cancer patients improves, more patients are at risk of developing local recurrence or a new primary tumour in previously irradiated areas. Technological advances in radiotherapy and imaging have made treatment of patients with high-dose re-irradiation possible, with the aim of long-term disease-free survival and even cure. However, high-dose re-irradiation with overlapping volumes of previously irradiated tissues is not without risks. Late, irreversible, and potentially serious normal tissue damage may occur because of injury to surrounding thoracic structures and organs at risk. In this Review, we aimed to report the efficacy and toxic effects of high-dose re-irradiation for locoregional recurrent non-small-cell lung cancer. Our findings indicate that high-dose re-irradiation might be beneficial in selected patients; however, patients and physicians should be aware of the scarcity of high-quality data when considering this treatment.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleHigh-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentRadiation Oncology, University Hospitals Leuven/KU Leuven, Leuven, Belgium. Eleen
dc.identifier.journalThe Lancet. Oncologyen
html.description.abstractAs the prognosis of lung cancer patients improves, more patients are at risk of developing local recurrence or a new primary tumour in previously irradiated areas. Technological advances in radiotherapy and imaging have made treatment of patients with high-dose re-irradiation possible, with the aim of long-term disease-free survival and even cure. However, high-dose re-irradiation with overlapping volumes of previously irradiated tissues is not without risks. Late, irreversible, and potentially serious normal tissue damage may occur because of injury to surrounding thoracic structures and organs at risk. In this Review, we aimed to report the efficacy and toxic effects of high-dose re-irradiation for locoregional recurrent non-small-cell lung cancer. Our findings indicate that high-dose re-irradiation might be beneficial in selected patients; however, patients and physicians should be aware of the scarcity of high-quality data when considering this treatment.


Files in this item

This item appears in the following Collection(s)

Show simple item record